Author: Alex Philippidis
Publisher: Genetic Engineering and Biotechnology News
Date: January 3, 2012
The weak economy of the past four years combined with cutbacks due to mergers and acquisitions have helped consolidate U.S. biopharma activity further within the nation’s largest life sciences clusters. Yet that has not stopped several other U.S. regions from trying to carve out their own piece of the life science pie.
The real estate firm Jones Lang LaSalle (JLL) highlighted nine examples of what it called emerging bioclusters. The regions in descending order as ranked by JLL are Minneapolis, Raleigh-Durham, Seattle, Chicago, Denver, Houston, Florida, Atlanta, and Indianapolis.
Arguably, though, the first three clusters on their list are far past that status. Minneapolis’ cluster has long been focused on medical device manufacturers anchored by the Mayo Clinic. Raleigh-Durham, which can also be called Research Triangle Park, has attracted several biopharma giants including Biogen Idec and GlaxoSmithKline. Read more here.